Global Agentic AI in Scientific Discovery Market Strategic Research Report

The global agentic AI in scientific discovery market sits at the intersection of artificial intelligence infrastructure and the accelerating industrialization of research workflows across pharmaceuticals, materials science, genomics, and climate science. Valued at approximately USD 1.8 billion in 2024, the market encompasses autonomous AI systems capable of formulating hypotheses, designing experiments, interpreting multi-modal data streams, and iterating research cycles with minimal human intervention. Unlike conventional AI-assisted tools that augment discrete analytical tasks, agentic systems operate across end-to-end discovery pipelines, compressing timelines that historically spanned years into months. The strategic significance of this market extends well beyond software licensing revenue—it is reshaping capital allocation in R&D-intensive industries and redefining the productivity frontier for corporate and academic research institutions globally.

Three structurally durable forces are propelling market expansion. First, the pharmaceutical industry's chronic productivity crisis—where average drug discovery costs have exceeded USD 2.5 billion per approved molecule—is creating urgent commercial incentives to deploy autonomous AI agents capable of screening billions of molecular configurations and self-directing in vitro validation cycles. Second, the maturation of large language model architectures into multi-step reasoning agents, combined with the proliferation of scientific foundation models trained on domain-specific corpora such as protein sequence databases and crystallographic archives, has crossed a technical threshold that makes end-to-end laboratory automation commercially viable. Third, sovereign and institutional R&D investment programs in the United States, China, and the European Union are explicitly designating AI-accelerated discovery as a national competitiveness priority, channeling procurement budgets toward agentic platforms. The principal restraint is the interpretability deficit: regulatory agencies including the FDA and EMA have not yet established clear evidentiary frameworks for discovery conclusions generated by autonomous agents, creating adoption friction in regulated industries.

This report provides a comprehensive quantitative and strategic analysis of the global agentic AI in scientific discovery market across the 2025–2032 forecast period, with a historical baseline extending to 2019. Coverage spans platform type, scientific domain application, and six key geographies, supported by detailed profiles of ten leading companies. The report is designed for corporate strategy teams evaluating build-versus-buy decisions, investment analysts assessing platform valuations and competitive moats, M&A advisors conducting sector mapping, and procurement leaders benchmarking vendor capabilities against enterprise research priorities.